Showing results (261-270 of 394) with videos related to
Sort By:
Pageof 40
Critical Reviews in Toxicology|March 27, 2019
Understanding outcomes and toxicological aspects of second generation metal-on-metal hip implants: a state-of-the-art reviewMichael Kovochich, Brent L Finley, Rachel Novick, et al.Journal of the American Society of Nephrology : JASN|May 16, 2008
Epithelial-to-mesenchymal transition in early transplant tubulointerstitial damageMatthew J Vitalone, Philip J O'Connell, Elvira Jimenez-Vera, et al.Biotherapy (Dordrecht, Netherlands)|January 1, 1992
Mouse/human chimeric anti-HIV-1 gp120 antibody to the principal neutralizing determinant: tolerability and pharmacokinetics in cynomolgus monkeys, Macaca fascicularisR S Liou, M S Fung, U Zühlke, et al.Cancers|August 14, 2025
Balancing Innovation and Safety: Prediction, Prevention, and Management of Pneumonitis in Lung Cancer Patients Receiving Novel Anti-Cancer AgentsSarah Liu, Daniel Wang, Andrew Robinson, et al.Abdominal Imaging|February 15, 2001
Diffusion-weighted MR imaging of the liver: distinguishing hepatic abscess from cystic or necrotic tumorJ H Chan, E Y Tsui, S H Luk, et al.Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|December 6, 2007
Prophylaxis against gram-positive organisms causing exit-site infection and peritonitis in continuous ambulatory peritoneal dialysis patients by applying mupirocin ointment at the catheter exit siteSunny S H Wong, Kwok Hong Chu, Au Cheuk, et al.Critical Reviews in Toxicology|April 9, 2026
A framework for assessing the safety of degraded pharmaceuticals for long-duration space missions - Part 1: framework developmentAndrey Massarsky, Veneese J B Evans, Ernest S Fung, et al.Critical Reviews in Toxicology|April 16, 2026
A framework for assessing the safety of degraded pharmaceuticals for long-duration space missions - Part 2: framework application in four case studiesAndrey Massarsky, Veneese J B Evans, Ernest S Fung, et al.Biotherapy (Dordrecht, Netherlands)|January 1, 1993
Pharmacokinetics of an HIV-1 gp120-specific chimeric antibody in patients with HIV-1 diseaseJ Schüpbach, H Günthard, M S Fung, et al.Journal of Virology|October 1, 1993
Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domainsJ P Moore, Q J Sattentau, H Yoshiyama, et al.Pageof 40